Latest Innovation News

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

WAM Global’s portfolio earnings grew 18% in FY2026, but valuation compression and currency losses left the investment portfolio down about 4.2% in Australian-dollar terms. The listed investment company declared a 13.2 cents per share fully franked full-year dividend, backed by a stated 5.2 years of dividend coverage.

Ceretas has completed the third milestone of its government-backed CUREator+ program, unlocking a final $692,578 non-dilutive funding tranche. The work delivered functional prototypes of proprietary neuronavigation software and a lift assist device intended to simplify operation of its next-generation Alzheimer’s ultrasound system.

ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.

James Hardie has raised its FY27 Free Cash Flow target to at least US$600 million and expects to deliver its US$125 million cost synergy target roughly a year early. The company also outlined a 4% to 7% annual organic growth ambition above market, while targeting net leverage below 2.0x by Q2 FY28.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Dotz Nano has secured a two-year supply agreement with Finnish direct-air-capture company Soletair Power, giving its carbon-capture sorbent a defined commercial customer and a contract value of EUR600,000. The deal is an important validation step, although the announcement does not disclose volumes, margins or delivery schedules.

Pathkey.AI has appointed Nanyang Technological University chip design and AI specialist Professor Anupam Chattopadhyay to the new Advisory Board supporting Chipforge. The appointment adds technical and commercialisation experience as the AI-native semiconductor platform moves from development towards a product launch, although no launch date or commercial contract was disclosed.

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.

Viridis Mining and Minerals has secured approval for a R$77.5 million BNDES financing facility, reducing the estimated senior debt still required for its Colossus rare earth project to about US$280 million. The 16-year facility carries an indicative current cost of approximately 4.8% and supports the project’s Brazilian processing and research infrastructure.

Peppermint Innovation has shifted from building its Philippines payments platform to commercialising it, but the FY26 report shows the business remains loss-making, balance-sheet constrained and dependent on future funding. The company reported A$217,720 in revenue, a A$2.40 million net loss and negative net assets of A$578,233.